Myriad Genetics (MYGN) Return on Sales (2009 - 2026)

Myriad Genetics has disclosed Return on Sales across 18 years of filings, most recently posting 0.0% for Q1 2026.

• In Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Sales retreated to 0.0% in Q1 2026, from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for MYGN reached as high as 0.0% in Q1 2025 and fell as low as 0.02% in Q2 2025.
• The 5-year median for Return on Sales is 0.0% (2026), against an average of 0.0%.
• Annual changes were most pronounced in 2022 — Return on Sales changed 0 bps — and 2023, when it decreased 1 bps.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2022, then surged by 33 bps to 0.0% in 2023, then slipped by 27 bps to 0.0% in 2024, then soared by 81 bps to 0.0% in 2025, then plunged by 352 bps to 0.0% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.